Xultophy® approved in Canada for the treatment of adults with type 2 diabetes... Read More

Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec... Read More

Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada... Read More

Global News

Press releases from the Denmark headquarters.

Media

Visit the pressroom of the website for our headquarters in Denmark where you can access the latest corporate stock exchange announcements, an image library, interim and annual reports and other relevant communication from Novo Nordisk A/S.

 

Media Contacts

For all media related inquiries, please contact the Corporate Communications team at Novo Nordisk Canada Inc.

Tel: 905-629-6612
Email: Kate Hanna - kxyh@novonordisk.com

For out of office hours, please contact Novo Nordisk, Global Media Relations
Tel: +45 4444 8888

If you have concerns regarding any Novo Nordisk product, please call customer care at 1-800-465-4334
or email nnci-drugsafety@novonordisk.com.